Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Indian J Pediatr ; 2006 Apr; 73(4): 335-41
Article in English | IMSEAR | ID: sea-80792

ABSTRACT

The advent of combination antiretroviral therapy for the treatment of human immunodeficiency virus (HIV) infection has dramatically changed the prognosis and quality of life of HIV-infected adults and children. To date, there are 21 antiretroviral agents available with only 11 agents being approved for the use in young children less than 6 years of age. The currently available antiretroviral agents belong to four different classes; nucleoside/nucleotide reverse transcriptase inhibitors (NRTI, NtRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), and a new class of fusion inhibitors (FI). It is recommended that the treatment regimen should be a combination of at least 3 drugs from different drug classes as this has been shown to slow disease progression, improve survival, and result in better virologic and immunologic responses. Treatment with antiretroviral agents is frequently complicated by the issues of adherence, tolerability, long term toxicity and drug resistance. Many efforts have been made to develop new antiretroviral agents with greater potency, higher tolerability profiles and better convenience. Some new agents are also effective against drug-resistant strains of HIV. Since 2001, there were 7 new antiretroviral agents and 2 fixed-dose multidrug formulations being approved for the treatment of HIV infection, most are approved only for use in adults. In this article, we will review new antiretroviral agents including emtricitabine, tenofovir disoproxil fumarate, atazanavir, fosamprenavir, tipranavir and enfuvirtide. Pediatric information on these drugs will be provided when available.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Humans
2.
Indian J Pediatr ; 2004 Jan; 71(1): 69-79
Article in English | IMSEAR | ID: sea-78378

ABSTRACT

Advances have been made in the understanding of the pathogenesis of mother-to-child transmission of human immunodeficiency virus (HIV). Most transmission occurs during delivery and after birth throught breastfeeding. For this reason, efforts to interrupt transmission have focused on peripartum period and infant feeding. This includes the use of antiretroviral therapy, elective cesarean section and avoidance of breastfeeding. This review summarizes recent major studies and new development on the prevention of mother-to-child HIV transmission. The application and the impact of such interventions in developing world is discussed. Prevention of mother-to-child transmission of HIV should now be integrated as part of basic maternal and child health services in developing countries.


Subject(s)
Adolescent , Adult , Anti-HIV Agents/therapeutic use , Developing Countries , Female , Follow-Up Studies , HIV Infections/prevention & control , Humans , Incidence , India/epidemiology , Infant, Newborn , Infectious Disease Transmission, Vertical/prevention & control , Male , Patient Education as Topic/methods , Pregnancy , Pregnancy Complications, Infectious/diagnosis , Prenatal Care/methods , Primary Prevention , Risk Assessment , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL